Items Tagged ‘BRCA1/2 mutation’

June 2nd, 2015

Combination of Iniparib, Gemzar®, and Carboplatin Active in Initial Treatment of Early-Stage Triple-Negative Breast Cancer


The combination of iniparib, Gemzar® (gemcitabine), and carboplatin appears promising in the initial treatment of patients with early-stage triple-negative breast cancer with a BRCA1/2 mutation. In addition, researchers have found ways to identify patients without a BRCA mutation who are likely to benefit. These findings were published in the Journal of Clinical Oncology. Breast cancers […]

View full entry

Tags: BRCA1/2 mutation, Breast Cancer, carboplatin, early-stage, gemzar, Iniparib, News, Stage I Node Negative Breast Cancer, Triple Negative Breast Cancer